This project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement number 604531
The AMCARE Project - Mending damaged hearts
AMCARE is a European research programme with 10 academic, industrial and clinical partners that aims to develop new stem-cell based regenerative therapies to treat patients with damaged hearts following Myocardial Infarction (MI - stroke). Biomaterials will be utilised to deliver these therapies to the heart and to keep them in place while the regeneration occurs.
What happens when you have a myocardial infarction?
Cardiovascular disease is a leading cause of morbididty and mortality, killing an estimated 17 million people every year. According to the European Society of Cardiology, every sixth man and every seventh woman in Europe will die from MI. AMCARE aims to reduce mI associated morbidity and mortality through the design of convergent cardiac stem cell, biomaterial and minimally invasive delivery device technologies.
More information is available on the AMCARE project website
The AMCARE project rationale: a specialised delivery device is used for minimally invasive delivery of hydrogel bound cardiac progenitor cells to the damaged myocardium to facilitate tissue regeneration, aided by the release of growth factors locally.
Latest AMCARE news
November 2016 - AMCARE research featured in The Translational Scientist
Prof Garry Duffy was interviewed for an article in November 2016 edition of The Translational Scientist magazine entitled Biomaterials at the Heart of Regeneration. The article details research being carried out in the AMCARE project to deliver cardiac stem cells to the heart to regenerate damaged tissue after aMyocardial Infaction (MI).
September 2015 - AMCARE is demonstrated at the National Ploughing Championships in Ireland
Duffy Kelly Lab researchers presesented the AMCARE project at the SFI stand at National Ploughing Championships in Ireland 2015.